Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06580938 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT06580938: Clinical Trial Phase 1 study, sponsored by Pfizer.
NCT06580938 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06580938, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07921585) in people with cancer that has advanced or spread to other parts of the body. This study is seeking participants who have any of the following cancer types: * non-small cell lung cancer * colorectal cancer * bladder cancer * melanoma (a type of skin cancer) * kidney cancer * head and neck cancer Participants will receive the study medicine PF-07921585 alone or in combination with another study medicine called sasanlimab at the study clinic. PF-07921585 will be given as an infusion into a vein or as shots under the skin, once every 3 weeks. Sasanlimab will be given as shots under the skin, also once every 3 weeks. The experiences of participants receiving the study medicine will be studied to help see if the study medicine is safe and effective. Participants may receive study medicine for up to 2 years, depending on how the cancer responds to the study treatment. Participants may continue receiving study medicine after 2 years if there are any benefits from the study treatment. Participants will attend visits once every 3 weeks with the first 9 weeks having more frequent visits, to check the safety of the study treatment.
Primary Outcome
Specific adverse events occurring during the first 21 days of study medication and considered at least possibly-related to study medication
Interventions
- BIOLOGICAL Sasanlimab
- BIOLOGICAL PF-07921585
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2024-11-11 |
| Est. Completion | 2025-07-14 |
| Phase | Phase 1 |
Why NCT06580938 stopped before completion
NCT06580938 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Sasanlimab is the first listed.
NCT06580938 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06580938 about?
NCT06580938 is a clinical study titled "A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer". The purpose of this study is to learn about the safety and effects of the study medicine (called PF-07921585) in people with cancer that has advanced or spread to other parts of the body. This study is seeking participants who have any of the following cancer types: * non-small cell lung cancer * ...
What is the current status of trial NCT06580938?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2024-11-11. Estimated completion is 2025-07-14.
What interventions are being tested in trial NCT06580938?
The interventions under investigation include: Sasanlimab (BIOLOGICAL), PF-07921585 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06580938?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06580938's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI